Explore Jobs
Find Specific Jobs
Explore Careers
Explore Professions
Best Companies
Explore Companies
FibroGen revenue
FibroGen's revenue is $29.6 million.
What is FibroGen's revenue?
- FibroGen's revenue growth from 2014 to 2024 is -78.47%.
- FibroGen has 461 employees, and the revenue per employee ratio is $64,253.
- FibroGen's peak quarterly revenue was $191.6M in 2019(q2).
- FibroGen peak revenue was $256.6M in 2019.
- FibroGen annual revenue for 2023 was 46.8M, -66.74% growth from 2022.
- FibroGen annual revenue for 2024 was 29.6M, -36.71% growth from 2023.
On This Page
We apply to jobs. You watch Netflix. Only $10.
FibroGen historical revenue
FibroGen's peak revenue was $256.6M in 2019. The peak quarterly revenue was $191.6M in 2019(q2).
FibroGen's revenue increased from $137.6m in 2014 to $29.6M currently. That's a -78.47% change in annual revenue.
FibroGen annual revenue
FibroGen annual revenue over time
| Fiscal Year / Year | FibroGen Revenue |
|---|---|
| 2014 | $137.6M |
| 2015 | $180.8M |
| 2016 | $179.6M |
| 2017 | $125.7M |
| 2018 | $213.0M |
| 2019 | $256.6M |
| 2020 | $176.3M |
| 2021 | $235.3M |
| 2022 | $140.7M |
| 2023 | $46.8M |
| 2024 | $29.6M |
How accurately did FibroGen's revenue projections match actual performance?
FibroGen annual growth
FibroGen saw the greatest revenue growth in 2018, when revenue increased by 69.46%.
FibroGen had the lowest revenue growth in 2022, when revenue changed by -40.19%.
FibroGen annual growth rate over time
| Year | FibroGen Growth |
|---|---|
| 2015 | 31%↑ |
| 2016 | -1%↓ |
| 2017 | -30%↓ |
| 2018 | 69%↑ |
| 2019 | 20%↑ |
| 2020 | -31%↓ |
| 2021 | 33%↑ |
| 2022 | -40%↓ |
| 2023 | -67%↓ |
| 2024 | -37%↓ |
FibroGen quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
FibroGen quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | - | - | - | $16.1M |
| 2015 | $16.3M | $120.6M | $19.5M | $24.4M |
| 2016 | $28.3M | $89.3M | $30.1M | $35.6M |
| 2017 | $29.4M | $30.3M | $40.6M | $30.7M |
| 2018 | $31.9M | $44.0M | $29.0M | $108.1M |
| 2019 | $23.9M | $191.6M | $33.2M | $8.0M |
| 2020 | $24.4M | $42.9M | $44.0M | $65.0M |
| 2021 | $38.4M | $24.4M | $156.0M | $16.5M |
| 2022 | $60.8M | $29.8M | $15.7M | $34.4M |
| 2023 | $36.2M | $44.3M | $40.1M | $27.2M |
| 2024 | $55.9M | $50.6M | $46.3M | ($123.3M) |
FibroGen Jobs Nearby
Do you work at FibroGen?
Is FibroGen transparent about its revenue structure?
FibroGen Financial Information
| CEO | Enrique A. Conterno |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 461 |
| Date Founded | 1993 |
| Headquarters | San Francisco, California |
| Number of Locations | 1 |
| Revenue | $29.6M |
| Net Income | -$293,654,000 |
| Gross Proft | $14.1M (2024) |
| PE Ratio | -80.07 |
| Tax Rate | 0.0% |
| Market Capitalization | $3.8B |
| Total Assets | $610,087,000 |
| Ticker | FGEN |
FibroGen Jobs You Might Like
FibroGen Financing
FibroGen received early financing of $100.0M on 2005-02-17.
| Series | Round Size | Date |
|---|---|---|
| Series Unknown | $100M | 02/2005 |
| Private Equity | $6M | 07/2012 |
| Series Unknown | $20M | 11/2014 |
| Post Ipo Equity | $62M | 07/2016 |
FibroGen Investors
| Investors | Security Type |
|---|---|
| The Goldman Sachs Group, Inc. | Series Unknown |
| Duquesne Capital Management | Series Unknown |
| APOTHECARY CAPITAL LLC | Series Unknown |
| Daiwa SMBC Capital | Series Unknown |
| Astellas Pharma Inc. | Series Unknown |
| Adage Capital Management | Series Unknown |
| Bio Fund Management Oy | Series Unknown |
| Brookside Capital Inc | Series Unknown |
| Merlin Biomed | Series Unknown |
| Sigma Capital Group | Series Unknown |
| T. Rowe Price Group, Inc. | Series Unknown |
| The Rosewood Corporation | Series Unknown |
| Corriente Biotechnology Partners | Series Unknown |
| ASTRAZENECA PLC | Post Ipo Equity |
FibroGen competitors
FibroGen's top competitor, Gilead Sciences, earned an annual revenue of $28.8B.
FibroGen's smallest competitor is Invitro with revenue of $710.0K last year.
| Company Name | Average Salary | Revenue | Employee Size | Job Openings |
|---|---|---|---|---|
| Exelixis | $108,978 | $2.2B | 484 | 102 |
| Cytokinetics | $89,800 | $18.5M | 130 | 104 |
| Geron | $56,851 | $77.0M | 15 | 2 |
| Genentech | $97,473 | $166.9M | 13,638 | 395 |
| Ultragenyx Pharmaceutical | $84,091 | $560.2M | 893 | 9 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 528 |
| CIMA Labs | $74,201 | $8.5M | 120 | - |
| ARCA biopharma | $45,049 | $1.0M | 15 | 1 |
| Spectrum Pharmaceuticals | $84,494 | $10.1M | 235 | 4 |
| ImClone Systems LLC | $81,730 | $39.0M | 180 | - |
Search for jobs
Related Company Revenues
Working At Related Companies
Related Company Jobs
FibroGen Highest Paying Jobs
Zippia gives an in-depth look into the details of FibroGen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about FibroGen. The employee data is based on information from people who have self-reported their past or current employments at FibroGen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by FibroGen. The data presented on this page does not represent the view of FibroGen and its employees or that of Zippia.
FibroGen may also be known as or be related to FIBROGEN INC, FibroGen, FibroGen Inc, FibroGen, Inc. and Fibrogen, Inc.